Contributions
Abstract: EP1660
Type: Poster Sessions
Abstract Category: Therapy - Risk management for disease modifying treatments
Introduction: Regular monitoring, with MRI assessments and blood samples, of MS patients on natalizumab exerts a significant burden on specialist centres. We investigated how the introduction of a pharmacy-led prescribing service impacted on the quality of monitoring and on the safety of patients.
Methods: Among patients receiving natalizumab at Imperial College Healthcare Trust (ICHT) MS centre, we evaluated the frequency of consultant reviews and recording of EDSS scores, of JC virus (JCV) status measurements and timeliness of MRI assessments before and after the introduction of a pharmacy-led prescribing and monitoring service.
Results: At ICHT 331 patients are treated with natalizumab each month; 839 prescription charts were reviewed by a pharmacist, between December 2016 and April 2018. Treatment duration ranged from 1 month to 9 years (mean 4.5 years, 53 doses) and EDSS at last infusion ranged from 1 to 7.5 (mean 3.9). Of the 299 patients reviewed in 2017, the most recent JCV status was negative in 40% (n=120) and positive in 60% (n=178) of patients; 28% (n=83) had low titre (≤ 1.5) and 32% (n=95) had high titre (> 1.5).
The pharmacy led prescribing and monitoring service was introduced in December 2016. Following this, a higher number of patients had EDSS score recorded (74% in 2016 to 86% in 2018; p< 0.001) and JCV status assessed (98% in 2016 to 100% in 2018; p=0.13). In addition, we observed a significant reduction of the number of patients, who had an overdue MRI. An MRI was considered overdue if the interval since the last scan was more than 12 months for JCV negative, 6 months for low positive or 3 months for high positive patients.
The number of MRIs overdue fell from 16% in 2016 to 5% in 2018, p< 0.001. In the subgroup with a high JCV titre the number of patients with an overdue MRI fell from 7.6% to 1.8%, (p< 0.001) and no patients had an MRI more than 3 months late. This indicated a significant improvement in timeliness of MRI surveillance.
Conclusion: A pharmacy-led prescribing and monitoring service is feasible, frees up time for the MS clinical team and greatly helps complying with natalizumab monitoring requirements, which overall improves patients safety.
Disclosure: R Dorsey-Campbell. Honoraria &/or conference sponsorship from Novartis, Biogen, Roche & Sanofi
Quinn T: Nothing to disclose
Felongco T:Nothing to disclose
Delacruz D: Nothing to disclose
Walters P: Nothing to disclose
Scalfari A: Nothing to disclose
Singh-Curry V: Nothing to disclose
Malik O: Nothing to disclose
Nicholas R: Nothing to disclose
Abstract: EP1660
Type: Poster Sessions
Abstract Category: Therapy - Risk management for disease modifying treatments
Introduction: Regular monitoring, with MRI assessments and blood samples, of MS patients on natalizumab exerts a significant burden on specialist centres. We investigated how the introduction of a pharmacy-led prescribing service impacted on the quality of monitoring and on the safety of patients.
Methods: Among patients receiving natalizumab at Imperial College Healthcare Trust (ICHT) MS centre, we evaluated the frequency of consultant reviews and recording of EDSS scores, of JC virus (JCV) status measurements and timeliness of MRI assessments before and after the introduction of a pharmacy-led prescribing and monitoring service.
Results: At ICHT 331 patients are treated with natalizumab each month; 839 prescription charts were reviewed by a pharmacist, between December 2016 and April 2018. Treatment duration ranged from 1 month to 9 years (mean 4.5 years, 53 doses) and EDSS at last infusion ranged from 1 to 7.5 (mean 3.9). Of the 299 patients reviewed in 2017, the most recent JCV status was negative in 40% (n=120) and positive in 60% (n=178) of patients; 28% (n=83) had low titre (≤ 1.5) and 32% (n=95) had high titre (> 1.5).
The pharmacy led prescribing and monitoring service was introduced in December 2016. Following this, a higher number of patients had EDSS score recorded (74% in 2016 to 86% in 2018; p< 0.001) and JCV status assessed (98% in 2016 to 100% in 2018; p=0.13). In addition, we observed a significant reduction of the number of patients, who had an overdue MRI. An MRI was considered overdue if the interval since the last scan was more than 12 months for JCV negative, 6 months for low positive or 3 months for high positive patients.
The number of MRIs overdue fell from 16% in 2016 to 5% in 2018, p< 0.001. In the subgroup with a high JCV titre the number of patients with an overdue MRI fell from 7.6% to 1.8%, (p< 0.001) and no patients had an MRI more than 3 months late. This indicated a significant improvement in timeliness of MRI surveillance.
Conclusion: A pharmacy-led prescribing and monitoring service is feasible, frees up time for the MS clinical team and greatly helps complying with natalizumab monitoring requirements, which overall improves patients safety.
Disclosure: R Dorsey-Campbell. Honoraria &/or conference sponsorship from Novartis, Biogen, Roche & Sanofi
Quinn T: Nothing to disclose
Felongco T:Nothing to disclose
Delacruz D: Nothing to disclose
Walters P: Nothing to disclose
Scalfari A: Nothing to disclose
Singh-Curry V: Nothing to disclose
Malik O: Nothing to disclose
Nicholas R: Nothing to disclose